Welcome to our dedicated page for Allarity Therapeutics news (Ticker: ALLR), a resource for investors and traders seeking the latest updates and insights on Allarity Therapeutics stock.
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. Founded in 2012, this innovative company is committed to unlocking the potential of new oncology products and rescuing failed drugs. Through its proprietary Drug Response Predictor (DRP®) technology, Allarity enhances patient selection and improves clinical outcomes in oncology.
Allarity boasts an impressive pipeline of in-licensed oncology therapeutics targeting difficult-to-treat cancers. Its lead product, stenoparib, a novel PARP/Tankyrase dual inhibitor, is currently being tested in advanced ovarian cancer patients. The DRP® companion diagnostic plays a crucial role in identifying patients who will benefit most from stenoparib, thereby increasing therapeutic efficacy and improving patient outcomes.
Recent achievements include significant advancements in their clinical trials, strategic financial restructurings, and compliance with Nasdaq listing requirements. The company's strategic pivot focuses on accelerating stenoparib's development, driven by promising Phase 2 trial data showing tumor shrinkage and long-term disease stability in heavily pre-treated ovarian cancer patients.
Allarity operates with research facilities in Denmark and a headquarters in the United States, underscoring its commitment to addressing significant unmet medical needs in cancer treatment. The company maintains an active presence in the clinical-stage pharmaceutical landscape, continually striving to develop novel personalized cancer treatments.
Visit www.allarity.com for more information and follow Allarity on LinkedIn and Twitter.
Allarity Therapeutics, Inc. (Nasdaq: ALLR) has priced a public offering to raise approximately $7.5 million through the sale of 2,869,330 shares of common stock, 7,130,670 pre-funded warrants, and 10 million common warrants. The combined price is set at $0.75 per share and common warrant, with warrants having an exercise price of $0.85 per share and a five-year expiration.
The closing is anticipated around April 21, 2023, subject to customary conditions. Funds will be used for accounts payable, accrued liabilities, and general corporate purposes, including redeeming series A preferred stock.
A.G.P./Alliance Global Partners is the sole placement agent for this offering. The securities are offered under a registration statement effective as of April 18, 2023.
FAQ
What is the current stock price of Allarity Therapeutics (ALLR)?
What is the market cap of Allarity Therapeutics (ALLR)?
What does Allarity Therapeutics specialize in?
What is DRP® technology?
What are the main products in Allarity Therapeutics’ pipeline?
Where is Allarity Therapeutics headquartered?
How has Allarity Therapeutics recently improved its financial standing?
What recent achievements has Allarity Therapeutics announced?
How does stenoparib work?
What are the benefits of using the DRP® companion diagnostic?
Has Allarity Therapeutics regained compliance with Nasdaq’s listing requirements?
What is the significance of the strategic pivot announced by Allarity Therapeutics?
